Join to View Full Profile
1101 Madison StSte 1500Seattle, WA 98104
Phone+1 206-991-2000
Fax+1 206-320-3001
Dr. Musa is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Fernanda Musa is an Gynecologic oncologist in Seattle, WA and is affiliated with multiple hospitals in the area, including the Swedish Cancer Institute and Providence Regional Medical Center Everett. She received her medical degree from Columbia University College of Physicians & Surgeons and has been in practice 10 years. She also speaks multiple languages, including Portuguese. She completed her fellowship in gynecologic oncology at New York University in New York and is experienced in complex gynecology, gynecologic oncology, clinical research, minimally invasive gynecologic surgery, and robotic surgery. She is interested in research and personalized cancer care and leads clinical trials at SCI.
Education & Training
NYU Grossman School of MedicineFellowship, Gynecologic Oncology, 2011 - 2015
NYU School of MedicineMS, Clinical Investigation, 2011 - 2013
New York Presbyterian Hospital (Cornell Campus)Residency, Obstetrics and Gynecology, 2007 - 2011
Columbia University Vagelos College of Physicians and SurgeonsClass of 2007- Duke UniversityBS, Biology, 1998 - 2002
- Escola Americana do Rio de Janeiro (EARJ)IB, 1991 - 1998
Certifications & Licensure
WA State Medical License 2017 - 2026
NY State Medical License 2011 - 2018
American Board of Obstetrics and Gynecology Obstetrics & Gynecology- American Board of Obstetrics and Gynecology Gynecologic Oncology
Clinical Trials
- A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Start of enrollment: 2022 Aug 29
- Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer Start of enrollment: 2023 Dec 28
- ADP-A2M4CD8 Monotherapy and in Combination with Nivolumab in HLA-A2+ Subjects with MAGE-A4 Positive Ovarian Cancer (SURPASS-3) Start of enrollment: 2023 Jun 26
- Join now to see all
Publications & Presentations
PubMed
- State of the art endocrine treatments for patients diagnosed with endometrial cancer in 2025.Fernanda B Musa, Kathleen N Moore, Vivek Podder, Brian M Slomovitz
Current Opinion in Obstetrics & Gynecology. 2025-04-01 - Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.Ramez N Eskander, Michael W Sill, Lindsey Beffa, Richard G Moore, Joanie M Hope
Nature Medicine. 2025-03-05 - 1 citationsThe doc versus the bot: A pilot study to assess the quality and accuracy of physician and chatbot responses to clinical questions in gynecologic oncology.Mary Katherine Anastasio, Pamela Peters, Jonathan Foote, Alexander Melamed, Susan C Modesitt
Gynecologic Oncology Reports. 2024-10-01
Press Mentions
Cancer Drug Shortages Lead to Heart-Wrenching Decisions at Washington HospitalsJune 5th, 2023
Committees
- Board of Directors, SGO 2022 - 2024
- Member, SGO Education Committee 2014 - 2016
Professional Memberships
- Member
- Fellow
- Society of Gynecologic OncologyMember
Other Languages
- Portuguese
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
